Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Measles

Measles

Part of Human Metapneumovirus Infection

20 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Measles

29 trials tracked for Measles: 24 in phase 3 or 4 and 10 with published results. The most-cited published study has 38 citations.

29Trials tracked
24Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 3 Phase 3 21 Phase 2 5
  1. Phase 3 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed · 38 cited
  2. Phase 3 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Completed · 30 cited
  3. Phase 3 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed · 20 cited
  4. Phase 3 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed · 19 cited
  5. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed · 14 cited
  6. Phase 3 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed · 13 cited
Show 23 more trials
  1. Phase 3 ProQuad® Intramuscular vs Subcutaneous Completed · 10 cited
  2. Phase 3 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed · 10 cited
  3. Phase 3 Safety Study of ProQuad® rHA in Infants (V221-037) Completed · 9 cited
  4. Phase 4 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Completed · 3 cited
  5. Phase 4 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Completed
  6. Phase 4 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed
  7. Phase 3 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed
  8. Phase 3 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed
  9. Phase 3 Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age Completed
  10. Phase 3 Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines Completed
  11. Phase 3 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) Completed
  12. Phase 3 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed
  13. Phase 3 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed
  14. Phase 3 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed
  15. Phase 3 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed
  16. Phase 3 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed
  17. Phase 3 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed
  18. Phase 3 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed
  19. Phase 2 A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age Completed
  20. Phase 2 ProQuad Dose Selection Study (V221-011)(COMPLETED) Completed
  21. Phase 2 Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Completed
  22. Phase 2 Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Completed
  23. Phase 2 Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Measles: what the trials found

Multiple vaccine formulations demonstrate high efficacy in inducing measles seropositivity or meeting antibody concentration cut-off values. Specifically, MR vaccines administered at 6 months showed 94% seropositivity at the 9-month visit 1 and 99-100% seropositivity by the 11-month visit 1. Other formulations including Priorix [6, 8], ProQuad® [5, 9, 10], and various MMRV combinations [13, 16, 20] consistently demonstrated high rates of participants meeting antibody response criteria for measles (ranging from approximately 90.8% to over 99% across different trials) [5, 6, 8, 9, 10].

Evidence also supports the efficacy of specific combinations and specialized formulations. A Japanese encephalitis chimeric virus vaccine combined with MMR showed high seroconversion rates for both components 15, while a live attenuated SA 14-14-2 Japanese Encephalitis vaccine demonstrated over 98% measles seropositivity 56 days post-vaccination 2. Additionally, specific trials confirmed that various multi-antigen vaccines (including those for mumps, rubella, and varicella) successfully induced measurable antibody titers against the measles virus [13, 16, 20].

For the clinician treating this condition

  • Multiple vaccine platforms (MR, MMRV, and combination products like ProQuad® and Priorix) consistently demonstrate high rates of measles seropositivity or meeting defined antibody cut-off values.
  • Clinical data confirms that infants receiving MR vaccines at 6 months achieve high seropositivity by the 9-month and 11-month marks 1.
  • Safety profiles for these vaccinations include reported instances of local reactions, fever, and other systemic symptoms across various trial designs [7, 11, 12, 13].

AI synthesis of 3 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
GSK investigational MMRV vaccine shows comparable immunogenicity to licensed MMRV in healthy children
Pediatrics RCT
GSK investigational MMRV vaccine shows comparable immunogenicity to licensed MMRV in healthy children GSK MMRV vaccine shows comparable safety and immune response to licensed MMRV in young children
This randomized, multi-country phase II trial in 801 healthy children aged 4-6 years found that one dose of a GSK investigational MMRV vacci…
A Phase II trial in healthy children found the investigational GSK MMRV vaccine produced immune responses and safety similar to the licensed…
May 27, 2026
Survey finds physicians show stronger intergroup bias than public on vaccines
Infectious Disease
Survey finds physicians show stronger intergroup bias than public on vaccines Doctors Show Strong Bias Against Vaccine-Hesitant Patients
This review of an online survey in Japan involving 492 physicians and 5,252 members of the general public found that physicians exhibited hi…
Doctors often see themselves as targets of vaccine anger, but new data shows they also hold strong bias against patients who question vaccin…
medRxiv Apr 26, 2026
Measles incidence increased in Galmudug State, Somalia, from 2023 to 2024
Primary Care & Family Medicine Cohort
Measles incidence increased in Galmudug State, Somalia, from 2023 to 2024 Measles cases rose in Somalia between April 2023 and December 2024
This retrospective cross-sectional study of 1,705 suspected measles cases in Galmudug State, Somalia, found an increased incidence rate from…
Measles cases in Somalia's Galmudug State jumped from 4.9 to 8.1 per 10,000 people between 2023 and 2024, with most infections hitting child…
Frontiers Apr 17, 2026
Night-light intensity and temporal factors associated with increased measles incidence in Ethiopia
Primary Care & Family Medicine Cohort
Night-light intensity and temporal factors associated with increased measles incidence in Ethiopia A Simple Night Light Could Predict Your Child's Measles Risk
This retrospective spatio-temporal cohort analysis examined national measles surveillance data from Ethiopia between 2018 and 2024.
Satellite images of night lights reveal where measles outbreaks are most likely to happen, helping health officials target vaccination effor…
Frontiers Apr 9, 2026
Mass vaccination campaign conducted among Afghan evacuees in US after measles cases
Infectious Disease
Mass vaccination campaign conducted among Afghan evacuees in US after measles cases How did health officials respond to measles cases among Afghan evacuees?
A descriptive public health report details a mass vaccination campaign implemented among Afghan evacuees brought to the United States follow…
Public health officials launched a mass vaccination campaign to stop measles spread among Afghan evacuees arriving in the United States.
CDC Apr 5, 2026
WHO and CDC report updates on global measles cases and vaccination coverage trends
Infectious Disease
WHO and CDC report updates on global measles cases and vaccination coverage trends Global health report provides update on measles cases and vaccination coverage
A joint WHO/CDC surveillance report describes global measles epidemiology and vaccination coverage.
A global health report updates measles cases and vaccination coverage worldwide, reminding us this virus remains a concern needing ongoing a…
CDC Apr 5, 2026
Report describes worldwide progress toward regional measles elimination goals
Infectious Disease
Report describes worldwide progress toward regional measles elimination goals Global health report tracks progress toward eliminating measles worldwide
A report describes global progress toward regional measles elimination.
A global health report tracks progress toward eliminating measles worldwide, highlighting that stopping the spread remains a key public heal…
CDC Apr 5, 2026
Field report describes measles response effort among Afghan evacuees at New Jersey base
Infectious Disease
Field report describes measles response effort among Afghan evacuees at New Jersey base How did the military stop measles from spreading among Afghan evacuees?
A field report describes a public health response effort to contain measles among persons evacuated from Afghanistan at Joint Base McGuire-D…
When measles threatened Afghan evacuees at a New Jersey military base, public health teams mobilized immediately to stop the virus from spre…
CDC Apr 5, 2026
WHO African Region progress toward measles elimination assessed from 2017 to 2021
Infectious Disease
WHO African Region progress toward measles elimination assessed from 2017 to 2021 Is Africa getting closer to eliminating measles? A new report tracks progress
A WHO report describes progress toward measles elimination in the African Region from 2017 to 2021.
A new WHO report tracks progress toward eliminating measles in Africa, showing that ending the virus is a long road with many checkpoints al…
CDC Apr 5, 2026
Field report describes measles outbreak in central Ohio community
Infectious Disease
Field report describes measles outbreak in central Ohio community Measles outbreak hits central Ohio community. What does this mean?
An observational field report describes a measles outbreak in a central Ohio community.
A measles outbreak is actively spreading in a central Ohio community, prompting public health teams to investigate the source and protect vu…
CDC Apr 5, 2026
Report describes progress toward global measles elimination in worldwide population
Infectious Disease
Report describes progress toward global measles elimination in worldwide population Report describes global progress toward eliminating measles worldwide
A descriptive report outlines progress toward measles elimination worldwide.
A new report outlines the ongoing global effort to eliminate measles, highlighting steady progress toward stopping the disease from spreadin…
CDC Apr 5, 2026
Measles outbreak reported among individuals associated with a Chicago migrant shelter
Infectious Disease
Measles outbreak reported among individuals associated with a Chicago migrant shelter Measles outbreak reported at Chicago migrant shelter, health officials investigating
An outbreak report describes a measles outbreak among individuals associated with a migrant shelter in Chicago, Illinois.
A measles outbreak has been reported at a migrant shelter in Chicago, prompting a health investigation.
CDC Apr 4, 2026

Questions about Measles

What public health response was used for measles among Afghan evacuees in the US?

Public health officials in the US organized a mass vaccination campaign specifically for Afghan evacuees after measles cases were identified within that group.

Full answer →
Did measles cases increase in Galmudug State, Somalia between 2023 and 2024?

Yes, measles cases increased in Galmudug State, Somalia, rising from an incidence of 4.9 per 10,000 people in 2023 to 8.1 per 10,000 in 2024.

Full answer →

All Measles Articles